Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
A federal district court in Georgia issued a sweeping ruling that could potentially undermine the legal foundation of the Medicare Advantage (MA) Star Ratings program and invite additional challenges to policies established through sub-regulatory guidance. The court found that the Centers for Medicare and Medicaid Services (CMS) improperly relied on measures based on data not collected through the statutorily required measurement systems and failed to meet notice-and-comment requirements for certain measures.
In February 2026, Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) introduced the Break Up Big Medicine Act (S. 3822). The bipartisan legislation, referred to the Senate Judiciary Committee, aims to prohibit pharmacy benefit managers (PBMs), health insurers, and prescription drug or medical device wholesalers from being under common ownership with certain medical service providers or provider groups, including in-patient or outpatient pharmacies.
